Dario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced the successful launch of five new employer contracts, including its largest employer contract to date, covering 107,000 lives. The contracts, implemented during Q2 and Q3 2025, feature Dario's complete cardiometabolic suite.

The company's digital health solutions have demonstrated significant results: 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user. Clinical outcomes include a 1.4% reduction in eHbA1c for diabetes, 10% reduction in BMI for prediabetes, and 38% of users reducing blood pressure by one stage.

Dario maintains a robust pipeline of $67 million in commercial opportunities and targets approximately 40 new client signings by year-end 2025, representing a 35% increase over 2024.

Positive

• Secured five new employer contracts including largest employer to date, covering 107,000 lives
• Strong clinical outcomes: 23% reduction in hospitalizations and $5,000 reduction in employer costs per user
• Pipeline of commercial opportunities increased to $67 million
• 80% of new accounts in 2025 are for higher-value multi-condition programs
• On track for 40 new client signings in 2025, representing 35% growth over 2024

Negative

• Company not yet profitable, though moving towards profitability

New customer launches representing 107,000 lives covered reinforce Dario's B2B2C momentum and recurring revenue growth

Dario's multi-condition digital health solutions deliver real-time results for prediabetes, diabetes, and hypertension resulting in a 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user

80% of the new accounts signed in 2025 are for multi-condition programs

Pipeline of commercial opportunities increases to $67 million

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the launch of five new contracts with self-insured employers. All five programs went live during the second and third quarters of 2025 and feature Dario's full cardiometabolic suite, highlighting continued demand for integrated, multi-condition solutions.

"We believe that employer contracts continue to be a powerful driver of near-term growth for Dario," said Steven Nelson, Dario's President and Chief Commercial Officer. "Building on previously announced wins and these five recent employer contracts, and supported by our robust $67 million pipeline of opportunities across employers, health plans, and pharmaceutical clients, we remain confident in our ability to reach approximately 40 new client signings by year-end 2025—a 35% increase over 2024 and a meaningful milestone on our path to profitability. Most notably, one of these five contracts is with an employer that is our largest to date, which we believe demonstrates our continued momentum with the largest and most discerning companies looking to deploy value-driven digital health solutions to improve outcomes while reducing costs."

Dario's cardiometabolic suite helps improve quality of life for people living with prediabetes, diabetes and hypertension as demonstrated through the following:

• Diabetes: 1.4% reduction in eHbA1c
  • Dario's evidence-based, personalized approach takes the guesswork out of managing diabetes. A pocket-sized smart meter and unlimited test strips allow for quick testing anytime, anywhere – no batteries required. Access to certified coaches and educational content provide the right support at the right time.
• Prediabetes: 10% reduction in body mass index (BMI)
  • Dario helps members adopt healthy habits and reverse the prediabetes trend, using Dario devices and our motivating coaching program to get their weight to a healthy range. They get ideas for food and exercise that work for their lifestyle, resulting in changes that last.
• Hypertension: 38% of users reduced blood pressure by one stage
  • Dario gives people everything they need to stay on top of their blood pressure: a connected monitor, a world-class smart app, and detailed progress reports. Access to certified coaches and educational content provide the right support at the right time.

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that the launch of five new contracts with self-insured employers will contribute to annual recurring revenues beginning the third quarter of 2025; that the new customer launches reinforce B2B2C momentum and recurring revenue growth; that employer contracts will continue to be a powerful driver of near-term growth; the $67 million pipeline of commercial opportunities; that the Company remains confident in its ability to reach approximately 40 new client signings by year-end 2025; and that the new client signings are a meaningful milestone to its path to profitability. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corp. Corporate Contacts:

Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com

DarioHealth Corp. Investor Relations Contact:

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com 
+1-201-785-6310

Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/dario-secures-five-new-employer-contracts-across-cardiometabolic-suite-including-its-largest-employer-to-date-contributing-to-annual-recurring-revenues-beginning-q3-2025-302543576.html

SOURCE DarioHealth Corp.

FAQ

What new contracts did DarioHealth (DRIO) secure in Q2-Q3 2025?

DarioHealth secured five new employer contracts, including its largest employer contract to date, covering 107,000 lives. All contracts include Dario's full cardiometabolic suite.

What are the clinical outcomes of DarioHealth's (DRIO) cardiometabolic suite?

DarioHealth's solutions achieved a 1.4% reduction in eHbA1c for diabetes, 10% reduction in BMI for prediabetes, and 38% of users reduced blood pressure by one stage.

How much cost savings do employers achieve with DarioHealth (DRIO)?

Employers using DarioHealth's solutions achieve $5,000 cost reduction per user, with a 23% reduction in hospitalizations and 9% reduction in healthcare utilization.

What is DarioHealth's (DRIO) commercial pipeline value for 2025?

DarioHealth maintains a $67 million pipeline of opportunities across employers, health plans, and pharmaceutical clients.

What is DarioHealth's (DRIO) projected client growth for 2025?

DarioHealth targets approximately 40 new client signings by year-end 2025, representing a 35% increase compared to 2024.